2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1792 Final Results of a phase II multi-center investigator initiated study of frontline acalabrutinib, lenalidomide and rituximab in patients with high tumor burden follicular lymphoma

Paolo Strati, MD, Lei Feng, MS2, Luis Malpica, MD3, Jason Westin, MD, MS, FACP, FASCO4, Ranjit Nair, MD5, Chijioke C Nze, MD, MPH6, Hilary Ma7, Dai Chihara, MD, PhD8, Jared Henderson, PhD9, Daniela Duenas10, Cara Haymaker11, Marco Corbo12, Rajendra Labala13, Laura Murphy, RN14, Laurel Deaton15, Laura Ebarle, NP16, Melissa Ceballos17, Marissa Rivera18, Manasi Patel19, Zachary Hunzeker, MD20, Luis E. Fayad, MD21, Anath Christopher Lionel, MD, PhD22, Christopher R. Flowers Jr, MD, MS23, Sattva S Neelapu Sr, MD24
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, United States
12 Signios Bio, Foster City, United States
13 Signios Bio, Foster City, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
19 The University of Texas MD Anderson Cancer Center, Houston, United States
20 The University of Texas MD Anderson Cancer Center, Houston, United States
21 The University of Texas MD Anderson Cancer Center, Houston, United States
22 The University of Texas MD Anderson Cancer Center, Houston, United States
23 The University of Texas MD Anderson Cancer Center, Houston, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States

Introduction. In a phase 2 study including 24 patients with advanced stage follicular lymphoma (FL) and high tumor burden, 13 cycles of acalabrutinib, lenalidomide and rituximab (aR2) showed to be safe and effective, with a minimal residual disease eradication rate by phased variant enrichment and detection sequencing of 73% after 6 cycles and favorable biological effects on the circulating immune microenvironment (Nat Commun 2025). To further explore its activity and to investigate a shorter duration of treatment, the study was expanded to include additional 26 FL patients treated with 6 cycles only. An exploratory analysis of biological mechanisms of response and resistance related to the tissue resident immune microenvironment was also performed.

 

Methods. This phase 2 single arm study (NCT04404088) accrued patients at an academic center and at a community hospital between 09/2020 and 03/2024 (data cutoff 06/2026). Adult patients with previously untreated and advanced stage FL, grades 1 to 3A, with high tumor burden disease, defined as meeting indication for treatment per GELF criteria, were included. Treatment consisted of acalabrutinib lead-in at 100 mg PO twice a day for one 28-day cycle and continued for total of 13 cycles, lenalidomide 20 mg PO daily on days 1-21, during cycle 2-13, and rituximab 375 mg/m2 IV weekly during cycle 2, and on day 1 of cycle 3-13. In the FL expansion cohort (N=26), patients in complete response (CR) were allowed to discontinue treatment after 6 cycles. The primary endpoint was best CR rate per Lugano 2014 criteria. Whole exome sequencing and RNA sequencing were performed in a subset of tissue biopsies collected before initiation of treatment and at time of relapse or progression.

 

Results. We enrolled and treated 50 FL patients. Median age was 65 (range, 40-82), 5 (10%) were non-Caucasian and 18 (36%) were female; median largest lymph node size was 6.6 cm (1.5-16.3 cm), median maximum standardized uptake volume was 12.1 (4-61), and 36 (72%) patients had intermediate-high FL international prognostic Index (FLIPI) score.

Median number of cycles was 13 (range, 6-13); 10 (20%) patients required a dose reduction in lenalidomide (4 due to liver function test [LFT] elevation), and 1 (2%) in acalabrutinib (due to skin rash). The most common (>=10% of patients) grade 3-4 adverse events were neutropenia (42%), infection (22%), LFT elevation (16%), and skin rash (12%). Twenty-four (48%) patients required growth factor support for a median of 2 times (range, 1-8 times)

Best ORR was 100%, best CR rate was 88%, and median time to CR was 3 months (3-13 months).

After a median follow-up of 35 months (95%CI, 33-52 months), 18 (36%) patients had disease progression, including 7 (14%) with transformation, and 1 (2%) died while in CR of COVID19 infection. None of the baseline characteristics associated with risk of transformation. Median PFS was not reached, and the 2-year PFS rate was 78% (95% CI, 67-90%). On univariate analysis, the only 2 baseline characteristics significantly associated with lower 2-year PFS rate were presence of B symptoms (20% vs 84%, p=0.0003) and intermediate-high FLIPI-2 score (72% vs 100%, p=0.03); no significant difference in PFS was observed based on regimen duration (6 vs 13 cycles) or other prognostic scores, including FLIPI, PRIMA PI or FLIPI-24. At data cutoff, 3 patients died, 2 due to COVID19 (while in CR) and 1 due to transformed lymphoma. The 2-year OS rate was 96% (95% CI, 91-100%).

When comparing tissue samples collected at time of progression to those collected before initiation of treatment, and pre-treatment tissue samples of progressors to non-progressors, genetic pathways associated with inflammation and immune engagement rather than immune exhaustion or evasion (including innate immunity and antigen presentation) were significantly upregulated, and a significant enrichment in gene mutations associated with innate immunity and macrophage biology (including CD163, FCGR1A, CD36, and CHIT1) were observed.

 

Conclusion. Our results indicate that the addition of acalabrutinib to R2 is a safe and effective frontline non-chemotherapy regimen for FL patients, resulting in high CR rates, with a treatment duration as short as 6 cycles in case of CR. Further exploration of biological pathways relevant to the innate immunity may help enhance the efficacy of this novel biological regimen.

Paolo Strati, MD: Sobi, AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics - Research Funding; Roche-Genentech, Abbvie-Genmab, Ipsen, Kite/Gilead, Novartis, Incyte, Lilly, AstraZeneca-Acerta, BeOne, ADC Therapeutics, Merck - Consultancy (Includes expert testimony)